Sector: Health Care
Director information for ENANTA PHARMACEUTICALS INC (data for year 2025)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Brendan Luu | Chief Business Officer | 50 | [] | [] | 2025 |
| Bruce L. A. Carter, Ph.D. | non-executive Chairman of the Board | 81 | ["Affiliate Professor in the Department of Biochemistry at the University of Washington", "Executive Chairman of Immune Design Corp.", "President and Chief Executive Officer of ZymoGenetics, Inc.", "Chief Scientific Officer of Novo Nordisk", "Director of Mirati Therapeutics"] | [] | 2025 |
| Dr. Carter | ["Business and scientific experience as a pharmaceutical executive in Europe and the United States", "Chief executive officer of a biotechnology company", "Experience as a director of several companies in the industry"] | [] | 2025 | ||
| Jay R. Luly, Ph.D. | President and Chief Executive Officer; President, Director and Chief Executive Officer | 68 | ["Business and scientific experience as a pharmaceutical executive", "Chief executive officer of a biotechnology company", "Director of several companies in the industry", "Entrepreneur in Residence at Oxford Bioscience Partners", "Senior Vice President, Research and Development Operations at Millennium Pharmaceuticals", "Senior Vice President, Drug Discovery and Preclinical Development at LeukoSite, Inc.", "Senior drug discovery positions at Abbott Laboratories"] | [] | 2025 |
| Kristine Peterson | 65 | ["over 30 years of senior executive experience", "commercial and business leadership roles in pharmaceutical and biotechnology industry", "CEO of Valeritas, Inc.", "executive management", "sales and marketing experience in large pharmaceutical companies", "sales and marketing experience in smaller biotechnology companies", "public company board experience"] | [] | 2025 | |
| Lesley Russell | Director | 64 | ["Chief Medical Officer of Innocoll Holdings Plc.", "Chief Operating Officer and Chief Medical Officer of TetraLogic Pharmaceuticals", "medical executive with Cephalon, Inc.", "Senior Vice President and Global Head, Research and Development for Global Branded Products", "held positions in medical research at US Bioscience, Eli Lilly and Amgen"] | [] | 2025 |
| Mark G. Foletta | Lead Director | 64 | ["Chief Financial Officer and Executive Vice President of Tocagen, Inc.", "Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc.", "Vice President, Finance and Chief Financial Officer of Amylin", "management positions with Intermark, Inc. and Triton Group Ltd.", "Audit Manager with Ernst & Young", "interim CFO of Biocept, Inc.", "considerable audit and financial experience in the biotechnology and healthcare sectors"] | [] | 2025 |
| Nathaniel S. Gardiner, J.D. | [] | [] | 2025 | ||
| Scott T. Rottinghaus, M.D. | Chief Medical Officer | 51 | [] | [] | 2025 |
| Tara Kieffer, Ph.D. | [] | [] | 2025 | ||
| Tara L. Kieffer, Ph.D. | Chief Product Strategy Officer | 47 | [] | [] | 2025 |
| Terry C. Vance | Chief Business Officer of BioMotiv, LLC | 68 | ["business and financial experience as a venture capital investor", "investment banker experience", "founding member of EGS Healthcare", "founding partner in Eagle Advisors"] | [] | 2025 |
| Yat Sun Or, Ph.D. | Chief Scientific Officer | 73 | [] | [] | 2025 |
| Yujiro S. Hata | Chief Executive Officer | 50 | ["executive management", "business and corporate development", "M&A experience in biotechnology companies"] | [] | 2025 |
